SecBot SecBot

PLRX

PLIANT THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001746473 Biotech & Drug Discovery
$0.6930 −0.00 (−0.57%)
Nov 16 4:00 PM ET · prev $0.6970
Market cap
$45.9M
Nano cap
Median target
$2.00
+189% · range $2.00–2.00
1 year
−58.0%
from $1.65 · Nov 17
30 days
−22.9%
from $0.8990
52-week range
$0.6930–1.65
at the low
Avg volume 20D
354.2K
Nov 16 spike 999.0K
Short interest
4.88M
≈7.9% of shares · +5.3%
Days to cover
16.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 6 added (0 new), 10 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.388 → −$0.360 over 90 days. 2 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +5.3% to 4.88M shares. 16.2 days to cover, ≈7.9% of shares.

  • TrendDOWNTREND

    28% below its 50-day average. New closing low $0.6930 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCADD194,878$210.5K
MORGAN STANLEYTRIM146,826$158.6K
JPMORGAN CHASE & CONEAR_EXIT107,629$116.2K
UBS Group AGNEAR_EXIT101,658$109.8K
SIMPLEX TRADING, LLCDOUBLED54,171$58.5K
Squarepoint Ops LLCTRIM27,606$29.8K
Invesco Ltd.NEAR_EXIT21,830$23.6K
FEDERATED HERMES, INC.TRIM15,288$16.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Mar 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +189%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Mar 13, 2026Canaccord Genuity
MAINTAIN
MAINTAINHold
Mar 12, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Nov 7, 2025RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 10, 2025JP Morgan
DOWNGRADE
DOWNGRADEUnderweight
Aug 8, 2025Piper Sandler
MAINTAIN
MAINTAINOverweight
Mar 18, 2025HC Wainwright & Co.
REITERATE
REITERATENeutral

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
Raben David
Chief Medical Officer
Oct 1, 2026
AWARD575,000 sh
Jul 9, 2026
Iannone Robert
Director
Jul 9, 2026
AWARD60,000 sh
Jul 9, 2026
Borellini Flavia
Director
Jul 9, 2026
AWARD60,000 sh
Jun 11, 2026
Huh Hoyoung
Director
Jun 11, 2026
AWARD70,000 sh
Jun 11, 2026
Cline Darren S
Director
Jun 11, 2026
AWARD70,000 sh
Jun 11, 2026
Curnutte John T
Director
Jun 11, 2026
AWARD70,000 sh
Jun 11, 2026
Krognes Steve E.
Director
Jun 11, 2026
AWARD70,000 sh
Jun 11, 2026
MCCOURT Thomas A
Director
Jun 11, 2026
AWARD70,000 sh

Earnings setup

Estimates
−$0.36
EPS estimate, this quarter
+7%
estimate change, 90 days
2↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.36-$0.36–-$0.36+2.8%$0.00
Next Q🔒 Fresh data, subscribers only
Current FY-$1.44-$1.47–-$1.42-0.7%$0.00
Next FY-$1.29-$1.47–-$0.94-0.8%$0.00

Short side

FINRA· Oct 30, 2026
4,881,070
shares short
+5.3%
vs prior settlement
16.2
days to cover
≈7.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Pliant Therapeutics reported Q3 2026 net loss of $24.4M ($0.39 per share), slightly narrower than the $26.3M loss a…
PRESS-RELEASE · Impact 4/10
Nov 12, 2026 Earnings
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment
Oct 1, 2026 Insider
Raben David was granted 575,000 shares
Chief Medical Officer
Sep 30, 2026 Inst.
JANE STREET GROUP, LLC · ADD
194,878 shares ($210.5K)
Sep 30, 2026 Inst.
MORGAN STANLEY · TRIM
146,826 shares ($158.6K)
Aug 18, 2026 Press
Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for…
Impact 4/10
Jul 9, 2026 Insider
Iannone Robert was granted 60,000 shares
Director
Jul 9, 2026 Insider
Borellini Flavia was granted 60,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 12, 2026
Earnings
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment
Nov 12, 2026
Earnings result
PLRX Q3 2026 Earnings: EPS $-0.39 (-3.3% vs est)
Nov 9, 2026
Company news
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of…
Nov 6, 2026
Earnings date
PLRX Q3 2026 Earnings Scheduled · 2026-11-06
Nov 5, 2026
Earnings date
PLRX Q3 2026 Earnings Scheduled · 2026-11-05

SecBot reports

7 filings · 1 press release · 1 bullish · 1 bearish · 1 mixed · 4 neutral
All PLRX filing & press-release reports (8)